Kingman, Martha S.; Chin, Kelly. Safety Recommendations for Administering Intravenous Prostacyclins in the Hospital.
Critical Care Nurse (CRIT CARE NURSE), 2013 Oct; 33 (5): 32-41. (37 ref)

Fuentes, Amaris; Coralic, Aida; Dawson, Kyle L. A new epoprostenol formulation for the treatment of pulmonary arterial hypertension. American Journal of Health-System Pharmacy (AM J HEALTH SYST PHARM AJHP), 2012 Aug 15; 69 (16): 1389-93.

Buckley, Mitchell S, et al. “Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review.” Core evidence 9(2014):71-80.

Sitbon, Olivier, et al. “EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.” The American heart journal 167.2 (2014):210-7.

Shirai, Yuichiro, et al. “Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center.” Modern rheumatology 23.6 (2013):1211-20.

Fuentes, Amaris, Aida Coralic, and Kyle L. Dawson. “A new epoprostenol formulation for the treatment of pulmonary arterial hypertension.” American journal of health-system pharmacy 69.16 (2012):1389-93.

Oudiz, Ronald J, and Harrison WFarber. “Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review.” The American heart journal 157.4 (2009):625-35.

DynaMed Entry for ” target=”_blank”>Epoprostenol
On the left look at Dosage and Administration and Cautions and Adverse Effects

Searched PubMed, DynaMed, and CINAHL. Keywords: Epoprostenol, patient safety, administration